Stock ATNM ACTINIUM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Actinium Pharmaceuticals, Inc.

Equities

ATNM

US00507W2061

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 21:00:00 03/05/2024 BST 		5-day change 1st Jan Change
8.96 USD +2.40% Intraday chart for Actinium Pharmaceuticals, Inc. +30.42% +76.38%
04-26 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-18 Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 35.86 106 132.4 271.4 139.3 266.9 - -
Enterprise Value (EV) 1 35.86 106 132.4 271.4 62.58 259.6 266.9 266.9
P/E ratio -1.45 x -4.26 x -5.01 x -7.77 x -2.78 x -6.04 x -31.1 x 5.98 x
Yield - - - - - - - -
Capitalization / Revenue - - 116 x 263 x 1,719 x - 4.2 x 1.87 x
EV / Revenue - - 116 x 263 x 773 x - 4.2 x 1.87 x
EV / EBITDA - -5.06 x -5.42 x -8.12 x -1.22 x -5.05 x 4.65 x 1.26 x
EV / FCF - -4.85 x -6.31 x 32.8 x -1.32 x -4.61 x -6.44 x 31.7 x
FCF Yield - -20.6% -15.9% 3.05% -75.9% -21.7% -15.5% 3.16%
Price to Book - 2.23 x 1.81 x - 3.72 x -9.63 x -7.41 x -
Nbr of stocks (in thousands) 5,490 13,587 22,031 25,483 27,413 29,783 - -
Reference price 2 6.531 7.800 6.010 10.65 5.080 8.960 8.960 8.960
Announcement Date 08/05/20 31/03/21 25/03/22 31/03/23 29/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - 1.144 1.03 0.081 - 63.47 142.4
EBITDA 1 - -20.96 -24.44 -33.4 -51.13 -51.4 57.4 211.3
EBIT 1 -22.07 -22.39 -24.96 -34.1 -51.92 -48.54 -8.219 67.15
Operating Margin - - -2,182.17% -3,311.07% -64,098.77% - -12.95% 47.16%
Earnings before Tax (EBT) 1 -21.9 -22.22 -24.77 -33.02 -48.82 -47.23 -3.083 67.15
Net income 1 -21.9 -22.22 -24.77 -33.02 -48.82 -47.23 -6.974 55.52
Net margin - - -2,165.56% -3,205.53% -60,269.14% - -10.99% 38.99%
EPS 2 -4.500 -1.830 -1.200 -1.370 -1.830 -1.483 -0.2878 1.498
Free Cash Flow 1 - -21.87 -21 8.278 -47.49 -56.3 -41.43 8.43
FCF margin - - -1,835.58% 803.69% -58,627.16% - -65.28% 5.92%
FCF Conversion (EBITDA) - - - - - - - 3.99%
FCF Conversion (Net income) - - - - - - - 15.18%
Dividend per Share - - - - - - - -
Announcement Date 08/05/20 31/03/21 25/03/22 31/03/23 29/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 0.023 0.94 0.045 0.045 - - - - 0.081 - - - - 1.441 20.69
EBITDA 1 -7.911 -5.027 -7.67 -9.578 -11.13 -11.4 -15.43 -14.15 -10.14 -9.381 -11.4 -14.1 -16.4 - -
EBIT 1 -8.048 -5.164 -7.85 -9.799 -11.29 -11.58 -15.64 -14.35 -10.34 -9.597 -10.95 -12.65 -14 -15.86 3.188
Operating Margin -34,991.3% -549.36% -17,444.44% -21,775.56% - - - - -12,769.14% - - - - -1,100.42% 15.41%
Earnings before Tax (EBT) 1 -8.01 -5.129 -7.767 -9.474 -10.65 -11.04 -15.18 -13.28 -9.324 -8.67 -12.57 -13.23 -12.8 -15.86 3.188
Net income 1 -8.01 -5.129 -7.767 -9.474 -10.65 -11.04 -15.18 -13.28 -9.324 -8.67 -12.57 -13.23 -12.8 -15.86 1.705
Net margin -34,826.09% -545.64% -17,260% -21,053.33% - - - - -11,511.11% - - - - -1,100.42% 8.24%
EPS 2 -0.3600 -0.2300 -0.3300 -0.3800 -0.4300 -0.4300 -0.5800 -0.4900 -0.3300 -0.3100 -0.4367 -0.4400 -0.4000 -0.4700 -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 25/03/22 13/05/22 12/08/22 14/11/22 31/03/23 15/05/23 14/08/23 02/11/23 29/03/24 26/04/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - - - 76.7 7.22 - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -21.9 -21 8.28 -47.5 -56.3 -41.4 8.43
ROE (net income / shareholders' equity) - - - - -94.9% - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - 3.500 3.320 - 1.370 -0.9300 -1.210 -
Cash Flow per Share 2 - - - - -1.780 -1.540 -0.3800 -
Capex - 0.25 0.13 0.37 0.15 - 0.68 1.85
Capex / Sales - - 11.63% 35.53% 188.89% - 1.07% 1.3%
Announcement Date 08/05/20 31/03/21 25/03/22 31/03/23 29/03/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
8.96 USD
Average target price
25.47 USD
Spread / Average Target
+184.23%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ACTINIUM PHARMACEUTICALS, INC. Stock Actinium Pharmaceuticals, Inc.
+76.38% 267M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
ARGENX SE Stock argenx SE
+4.40% 22.94B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+313.59% 8.49B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ATNM Stock
  4. Financials Actinium Pharmaceuticals, Inc.